BLT 6.78% 5.5¢ benitec biopharma limited

Benitec cancelled OPMD

  1. 1,327 Posts.
    lightbulb Created with Sketch. 71
    Sydney, Australia, 6 June 2019: Benitec Biopharma Limited (“Benitec” or the “Company”) (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW) today announced the termination of the License and Collaboration Agreement with Axovant Sciences, as the Benitec team endeavors to conduct several additional exploratory analyses prior to the initiation of the clinical study in order to potentially improve the biological efficacy of the compound via further optimization of the proprietary delivery method employed to dose the target tissues. Preclinical data derived from recently concluded in vivo evaluations of AXO-AAV-OPMD (formerly designated as BB-301) in two distinct large animal species suggest that the opportunity exists to further improve the biological efficacy of the compound via additional optimization of the proprietary delivery method employed to dose key target tissues that underlie the morbidity and mortality associated with the progression of Oculopharyngeal Muscular Dystrophy. The initial biological efficacy profile observed for BB-301 following in vivo testing in the murine model of Oculopharyngeal Muscular Dystrophy, including full correction of the disease phenotype, remains unchanged. However, the Benitec team endeavors to conduct several additional exploratory analyses prior to the initiation of clinical testing. Completion of the experimental work noted above would delay the initiation of the BB-301 clinical study beyond the timelines that were initially outlined following the execution of the License and Collaboration Agreement between Benitec Biopharma and Axovant Sciences. As such, the License and Collaboration Agreement between Benitec Biopharma and Axovant Sciences will be terminated, and all rights and licenses granted to Axovant Sciences will cease, including the rights to BB-301, which was in preclinical development for the treatment of Oculopharyngeal Muscular Dystrophy, and all other early stage research collaboration programs. The termination of the License and Collaboration Agreement will be effective on September 3, 2019. Updates will be provided over the coming months regarding the new research programs to be advanced by the Benitec team.
 
watchlist Created with Sketch. Add BLT (ASX) to my watchlist
(20min delay)
Last
5.5¢
Change
-0.004(6.78%)
Mkt cap ! $14.13M
Open High Low Value Volume
5.9¢ 5.9¢ 5.5¢ $82.08K 1.450M

Buyers (Bids)

No. Vol. Price($)
1 242 5.5¢
 

Sellers (Offers)

Price($) Vol. No.
5.6¢ 23648 1
View Market Depth
Last update - 16.10pm 27/06/2019 (20 minute delay) ?
(live)
Last
5.6¢
  Change
-0.004 ( 5.08 %)
Open High Low Volume
5.7¢ 5.8¢ 5.5¢ 406802
Last updated 15.33pm 27/06/2019 (live) ?
BLT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.